Who is the new Chief Financial Officer at TransCode Therapeutics?

TransCode Therapeutics named John Tattory Chief Financial Officer, announced September 10, 2026.

Which similar companies made leadership changes around the same time?

Novocure (September 9, 2026), Abivax (September 7, 2026), Vyome Holdings (September 14, 2026) and Acrivon Therapeutics (August 31, 2026) also announced leadership changes within 45 days of TransCode Therapeutics.

TransCode Therapeutics Appoints John Tattory as Interim Chief Financial Officer

PUBLIC · RNAZSep 10, 2026

Position

Chief Financial Officer

Company

TransCode Therapeutics

John Tattory

BostonBiotechnologyHealth CareMedicalTherapeutics

Description

TransCode Therapeutics announced the retirement of its Chief Financial Officer, Tom Fitzgerald, effective immediately. John Tattory will take over as Interim Chief Financial Officer, bringing over 25 years of financial and operational experience to the role.

Quick answer

TransCode Therapeutics Appoints John Tattory as Interim Chief Financial Officer (September 10, 2026). TransCode Therapeutics is based in Boston, Massachusetts, United States.

Who is the new Chief Financial Officer at TransCode Therapeutics?: TransCode Therapeutics named John Tattory Chief Financial Officer, announced September 10, 2026.
What did TransCode Therapeutics announce on September 10, 2026?: TransCode Therapeutics announced the retirement of its Chief Financial Officer, Tom Fitzgerald, effective immediately. John Tattory will take over as Interim Chief Financial Officer, bringing over 25 years of financial and operational experience to the role.
What does TransCode Therapeutics do?: TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.
Where is TransCode Therapeutics based?: TransCode Therapeutics is based in Boston, Massachusetts, United States.
Which similar companies made leadership changes around the same time?: Novocure (September 9, 2026), Abivax (September 7, 2026), Vyome Holdings (September 14, 2026) and Acrivon Therapeutics (August 31, 2026) also announced leadership changes within 45 days of TransCode Therapeutics.

Source: Fundz verified event record.

Other recent leadership changes in Medical and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

NovoCure Limited Announces Retirement of Director Timothy Scannell (September 9, 2026)
Abivax Appoints James Berger as Global Head of Marketing (September 7, 2026)
Vyome Appoints Jerry Leonard as Chief Financial Officer (September 14, 2026)
Acrivon Appoints Michaela Levin as Chief Business Officer (August 31, 2026)
Wave Life Sciences Appoints Monika Vnuk as Chief Business Officer (September 22, 2026)
Corcept Therapeutics Announces Resignation of President Sean Maduck (September 23, 2026)

Who to call at TransCode Therapeutics, and when

A new leader at TransCode Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

An alert the day TransCode Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at TransCode Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TransCode Therapeutics. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TransCode Therapeutics

Location

Boston, Massachusetts, United States

About

TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. Another of the company’s drug candidates, TTX-siPDL1, focuses on treating tumors by targeting a protein called Programmed death-ligand 1 (PD-L1). TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TransCode Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans